Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
The primary objective of this study is to compare the effect of treatment with olpasiran, to
placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or
urgent coronary revascularization in participants with atherosclerotic cardiovas...
Age: 18 - 85 years
Gender: All
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination
with talquetamab or teclistamab, and to characterize the safety and tolerability of
talquetamab or teclistamab when administered in combination with a PD-1 inhibitor.
Age: 18 years - 66+
Gender: All
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)
The purpose of this study is to evaluate the efficacy and safety of vericiguat in
participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically
those with symptomatic chronic HFrEF who have not had a recent hospitalization for heart
...
Age: 18 years - 66+
Gender: All
A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.
The purpose of the study is to assess if the addition of darolutamide to ADT compared with
ADT alone would result in superior clinical efficacy in participants with metastatic
hormone-sensitive prostate cancer (mHSPC) by progression-free survival.
The researcher...
Age: 18 years - 66+
Gender: Male
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or
ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of
ischemic stroke, intracerebral hemorrhage, or vascular death.
Age: 30 - 80 years
Gender: All
e-Motivación: Developing and Pilot Testing an App to Improve Latinos' Screening Colonoscopy Rates
Among Latinos, a fast growing and underserved population, Colorectal Cancer (CRC) is the third leading cause of cancer death in men and in women. Compared to non-Latino whites, Latinos are less likely to be diagnosed with localized CRC and more likely to be diagnosed wi...
Age: Birth - 66+
Gender: All
Novel Experimental COVID-19 Therapies Affecting Host Response
The overarching goal of the Master Protocol is to find effective strategies for inpatient
management of patients with COVID-19. Therapeutic goals for patients hospitalized for
COVID-19 include hastening recovery and preventing progression to critical illness,
mult...
Age: 18 years - 66+
Gender: All
Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism
There are many available treatments for pulmonary embolism (PE), but the best treatment for
this condition is not known. The HI-PEITHO study will compare two treatment options that are
both available on the market for the treatment of PE.
Patients will be random...
Age: 18 - 80 years
Gender: All
Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism
There are many available treatments for pulmonary embolism (PE), but the best treatment for
this condition is not known. The HI-PEITHO study will compare two treatment options that are
both available on the market for the treatment of PE.
Patients will be random...
Age: 18 - 80 years
Gender: All
Precision-Based Genomics in Prostate Cancer
Background: Prostate cancer is the most common cancer and the second leading cause of death in males in the United States. Researchers want to find additional gene mutations that may increase a man s risk for prostate cancer and may affect how aggressive the disease is....
Age: 18 years - 66+
Gender: Male
Precision-Based Genomics in Prostate Cancer
Background: Prostate cancer is the most common cancer and the second leading cause of death in males in the United States. Researchers want to find additional gene mutations that may increase a man s risk for prostate cancer and may affect how aggressive the disease is....
Age: 18 years - 66+
Gender: Male
LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy of PVSRIPO and PVSRIPO in Combination With Anti-PD-1/L1 Checkpoint Inhibitors in Patients With Advanced Solid Tumors
This is a Phase 1/2, open-label, multi-center, single arm basket study evaluating the
administration of PVSRIPO ± anti programmed cell death protein 1 (PD 1)/programmed
death-ligand 1 (PD L1) monoclonal antibody (mAb) (which will be referred to throughout this
pro...
Age: 18 years - 66+
Gender: All
Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors
The purpose of this research study is to see if the amount of vitamin D in ones blood makes it more or less likely to develop thyroid gland toxicity when being treated with immunotherapy that blocks the activity of proteins called programed death-1(PD-1) or programmed d...
Age: 18 years - 66+
Gender: All
Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors
The purpose of this research study is to see if the amount of vitamin D in ones blood makes
it more or less likely to develop thyroid gland toxicity when being treated with
immunotherapy that blocks the activity of proteins called programed death-1(PD-1) or
progra...
Age: 18 years - 66+
Gender: All
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to
evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or
in rational, specified combinations in participants with unresectable, locally advance...
Age: Birth - 66+
Gender: All
A Communication Tool to Assist Older Adults Facing Dialysis Choices
The purpose of this study is to test the effect of the "Best Case/Worse Case" (BC/WC)
communication tool on receipt of palliative care and intensity of treatment at the end of
life, quality of life, and quality of communication for older patients with end-stage rena...
Age: 60 years - 66+
Gender: All
Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone on Morbidity (Events Indicating Disease Worsening) & Mortality (Death Rate) in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%
The purpose of this study is to evaluate the effect of finerenone compared to placebo (a
tablet without active substance) in the reduction of cardiovascular death (generally meaning
death due to disease of the heart or blood vessels) and total Heart Failure (HF) eve...
Age: 40 years - 66+
Gender: All
Antithrombotic Therapy to Ameliorate Complications of COVID-19 ( ATTACC )
Endothelial injury as a consequence of SARS-CoV-2 infection leads to a dysregulated host inflammatory response and activation of coagulation pathways. Macro- and micro-vascular thrombosis may contribute to morbidity, organ failure, and death. Therapeutic anticoagulation...
Age: 18 years - 66+
Gender: All
Antithrombotic Therapy to Ameliorate Complications of COVID-19 ( ATTACC )
Endothelial injury as a consequence of SARS-CoV-2 infection leads to a dysregulated host
inflammatory response and activation of coagulation pathways. Macro- and micro-vascular
thrombosis may contribute to morbidity, organ failure, and death. Therapeutic anticoagulati...
Age: 18 years - 66+
Gender: All
Cardiac Arrhythmias In Patients With Coronavirus Disease (COVID-19)
The objective of the study is to estimate the frequency of cardiac arrhythmias and
characterize the mode of death in patients with coronavirus disease (SARS-CoV-2; COVID-19).
The study will also evaluate the long term cardiac outcomes in patients previously diagnose...
Age: Birth - 66+
Gender: All